Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34371524/
doi: 10.1111/bcp.15029. Online ahead of print. 1 Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland. 2 Clinical Research Services Mannheim GmbH, Mannheim, Germany. 3 Preclinical Drug Metabolism and Pharmacokinetics, Idorsia Pharmaceuticals...
Conclusion: Daridorexant 50 mg can be administered concomitantly with gastric pH modifiers or with moderate CYP3A4 inducers without dose adaptation based on efficacy observed at lower doses in Phase 3 studies.
Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34480579/
doi: 10.1093/sleep/zsab224. Online ahead of print. 1 Idorsia Pharmaceuticals Ltd, Department of Clinical Pharmacology, Allschwil, Switzerland. 2 Altasciences Clinical Kansas, Inc., Kansas, United States. 3 Altreos, Research Partners, Inc., Toronto,...
Conclusions: In this large, valid human abuse potential study, daridorexant showed dose-related drug-liking among recreational sedative drug users with lower effects at the highest phase-3 dose, and similar effects at higher doses compared to supratherapeutic doses of suvorexant and zolpidem.
Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455402/
Insomnia, characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning (American Academy of Sleep Medicine 2014), chronically affects approximately 5-20% of the adult population (Roth...
Interpretation: Lower-sodium oxybate treatment resulted in a clinically meaningful improvement in idiopathic hypersomnia symptoms, with an overall safety profile consistent with that reported for narcolepsy. Lower-sodium oxybate was approved in August, 2021, by the US Food and Drug Administration for the treatment of idiopathic hypersomnia in...
Idiopathic Hypersomnia Severity Scale to better quantify symptoms severity and their consequences in idiopathic hypersomnia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34596041/
The IHSS is a valid and reliable tool to quantify IH symptoms, with four clinically severity score levels. The IHSS has adequate psychometric properties and can detect symptom changes after...
Conclusions: The IHSS is a valid and reliable tool to quantify IH symptoms, with four clinically severity score levels. The IHSS has adequate psychometric properties and can detect symptom changes after treatment. These findings should stimulate its use in clinical settings and in research studies.